Market Research Report
Acromegaly - Epidemiology Forecast - 2032
|Acromegaly - Epidemiology Forecast - 2032|
DelveInsight Business Research LLP
Content info: 75 Pages
Delivery time: 2-10 business days
DelveInsight's "Acromegaly- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The DelveInsight's Acromegaly epidemiology report gives a thorough understanding of Acromegaly by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. These hormones regulate many different bodily functions. In most patients, acromegaly is caused by the growth of a benign tumor (adenoma) arising from the pituitary gland. Symptoms of acromegaly include abnormal enlargement in bones of the hands, arms, feet, legs, and head. Enlargement of the bones in the jaws and the front of the skull are typically the most apparent bony changes.
Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.
Screening is recommended for all patients presenting with clinical features of acromegaly (such as mass tumor effects, systemic effects of GH/IGF-1 excess, cardiovascular and metabolic features, respiratory and bone/joint manifestations, and/or other endocrine consequences). However, screening may also be considered in patients with several medical conditions associated with acromegaly, such as type 2 diabetes mellitus, carpal tunnel syndrome, debilitating arthritis, hypertension, and sleep apnea. Biochemical screening is the first step for an acromegaly diagnosis. Endocrine Society guidelines and experts' consensus recommend using age- and sex-adjusted IGF-1 levels in combination with GH nadir during an oral glucose tolerance test (OGTT) to diagnose and rule out acromegaly. Measuring serum IGF-1 is usually the initial screening test.
Levels of GH in the blood can change throughout the day. A reliable way to track GH in the body is by measuring the level of IGF-I in the blood. In most cases, a high IGF-I level suggests that a person has acromegaly. An oral glucose tolerance test to confirm the diagnosis. For this test, the patient will drink a sugary liquid. A health professional will then test the blood every half hour for 2 h to measure growth hormone levels. The sugar in the drink will normally cause GH levels to fall. But if the body is making too much of the hormone, these levels will not go down enough-thereby confirming the diagnosis of acromegaly. If the blood tests confirm that the body is making too much GH, the doctor will conduct imaging tests to locate and measure the tumor that may be causing the problem.
The Acromegaly epidemiology section provides insights about historical and current Acromegaly patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Acromegaly epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total diagnosed prevalent cases of Acromegaly was 57,824 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032 segmented by seven major markets.
The disease epidemiology covered in the report provides historical as well as forecasted Acromegaly epidemiology [segmented as Total Diagnosed prevalent Cases of Acromegaly, Total Tumor origin-specific Cases of Acromegaly, Total Gender-specific Cases of Acromegaly, Total Tumor size Cases of Acromegaly, Total Treated Cases of Acromegaly] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Acromegaly epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current Acromegaly patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Acromegaly domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.